ACAD Q1 2019 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

ACADACADIA Pharmaceuticals Inc.

$4B

Q1 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$63M+28.8% YoY

Gross Profit

$58M92.7% margin

Operating Income

-$88M-139.2% margin

Net Income

-$85M-135.5% margin

EPS (Diluted)

$-0.59

QoQ Revenue Growth

+5.7%

Cash Flow

Operating Cash Flow

-$64M

Free Cash Flow

-$65M

Stock-Based Comp.

$20M

Balance Sheet

Total Assets

$501M

Total Liabilities

$83M

Stockholders' Equity

$418M

Cash & Equivalents

$98M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$63M	$49M	+28.8%
Gross Profit	$58M	$45M	+28.6%
Operating Income	-$88M	-$55M	-59.9%
Net Income	-$85M	-$54M	-57.1%